Results 201 to 210 of about 386,039 (382)

Cyclin Dependent Kinase 2 (CDK2) Inhibitors in Oncology Clinical Trials: A Review. [PDF]

J Immunother Precis Oncol
House I, Valore-Caplan M, Maris E, Falchook GS.   +3 more
europepmc   +1 more source

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

International Journal of Cancer, EarlyView.
Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner, Jayant Y. Gadrey, Scott A. Armstrong, Michael W. M. Kühn   +3 more
wiley   +1 more source

The Cyclin-Dependent Kinase activity modulates the central carbon metabolism in maize during germination. [PDF]

Physiol Plant
Lara-Núñez A, Garza-Aguilar SM, Páez-Franco JC, de Dios Galindo-de-la-Rosa J, Vallejo-Becerra V.   +4 more
europepmc   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy. [PDF]

Molecules
Kaszubski J, Gagat M, Grzanka A, Wawrzyniak A, Niklińska W, Łapot M, Żuryń A.   +6 more
europepmc   +1 more source

Limited association between HRR gene alterations and HRD in molecular tumor board cancer samples: Who should be tested for HRD?

International Journal of Cancer, EarlyView.
What's New? Currently, no published data on homologous recombination deficiency (HRD) testing in the setting of molecular tumor boards exist. This study in a cohort of 237 patients encompassing 24 different tumor entities assessed by a molecular tumor board shows that inactivating alterations of BRCA1/2 are not always associated with an elevated ...
Christoph Schubart, Lars Tögel, Maria Giulia Carta, Philip Hetzner, Lina Helbig, Charlotte Zaglas, Maria Ziegler, Robert Stöhr, Annett Hölsken, Juliane Hoyer, Fulvia Ferrazzi, Clemens Neufert, Sebastian Lettmaier, Marianne Pavel, Henriette Golcher, Sarina K. Mueller, Florian Fuchs, Carla E. Schulmeyer, Matthias W. Beckmann, Bernd Wullich, Abbas Agaimy, Andre Reis, Arndt Hartmann, Norbert Meidenbauer, Silvia Spoerl, Florian Haller, Evgeny A. Moskalev   +26 more
wiley   +1 more source

Correction: Absence of cyclin-dependent kinase inhibitor p27 or p18 increases efficiency of iPSC generation without induction of iPSC genomic instability. [PDF]

Cell Death Dis
Zhan Z, Song L, Zhang W, Gu H, Cheng H, Zhang Y, Yang Y, Ji G, Feng H, Cheng T, Li Y.   +10 more
europepmc   +1 more source

Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration

Proceedings of the National Academy of Sciences of the United States of America, 2012
M. K. Diril, Chandrahas Koumar Ratnacaram, V. Padmakumar, Tiehua Du, M. Wasser, V. Coppola, L. Tessarollo, P. Kaldis   +7 more
semanticscholar   +1 more source

Biphasic Regulation of Breast Cancer Cell Growth by Progesterone: Role of the Cyclin-Dependent Kinase Inhibitors, p21 and p27Kip1 [PDF]

, 1997
S. D. Groshong
openalex   +1 more source

Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients

International Journal of Cancer, EarlyView.
What's New? Circulating tumor cells can offer insights into treatment responses and metastatic recurrence, but current analysis methods are limited. Here, the authors tested a newly developed mass cytometry panel comprising biomarkers such as γH2AX and RAD51 in longitudinally monitored metastatic breast cancer patients.
Kathrin Niedermayer, Henning Schäffler, Georgios Vlachos, Sara Greco, Kerstin Pfister, Barbara Volz, Leonie Ott, Hans Neubauer, Bernhard Polzer, André Koch, Sabine Riethdorf, Tanja Fehm, Wolfgang Janni, Thomas W. P. Friedl, Brigitte Rack, Ellen Heitzer, Fabienne Schochter, Lisa Wiesmüller   +17 more
wiley   +1 more source